Immuneering Corporation (IMRX) delivered a return of 113.78% over the past year. Since IMRX does not currently pay dividends, the total return equals the price-only return.

A $10,000 investment in Immuneering Corporation one year ago would be worth $21,378 today, representing a gain of $11,378.

Immuneering Corporation (IMRX) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For IMRX, the total return equals the price-only return.

Yes, Immuneering Corporation (IMRX) outperformed the S&P 500 by 90.92 percentage points over the past year. IMRX delivered a total return of 113.78%, compared to the S&P 500's 22.86%. This 90.92pp alpha means investors in IMRX earned more than a passive S&P 500 index fund.

Immuneering Corporation (IMRX) experienced a maximum drawdown of -57.67% over the past year, declining from its peak on 2025-09-19 to its trough on 2026-06-10. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Here are Immuneering Corporation (IMRX)'s long-term returns with dividends reinvested. Over 10 years, the total return is -76.2% (-13.4% CAGR) — $10,000 would have grown to $2,382. Over 20 years: -76.2% total return (-6.9% CAGR) — $10,000 → $2,382. Over 30 years: -76.2% total return (-4.7% CAGR) — $10,000 → $2,382. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Immuneering Corporation's best calendar year was 2025 with a total return of 197.7%. Its worst year was 2022 with a total return of -71.5%. This range shows the volatility investors should expect — the difference between the best and worst year is 269.2 percentage points.